I hear you but we are not comparing apples with apples on the patient cohort here.
MSB are treating 100% of the sickest in their trials and looking for 70% success rate ideally.
This other treatment they are not treating just the 6% being hospitalized, they are treating the 100% who test positive for COVID with a 4.7% reduction in hospitalization on that whole 100% who they are treating. So then it comes down to - is it worth the cost to treat the 100% infected for a 4.7% improvement over doing nothing. That is the harsh reality of this one.
I say yes save everyone but governments won't in their cost benefit analysis.
72% reduction in hospitalisation from monoclonal antibodies, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |